i3 Health

i3 Health

Overview

i3 Health's mission is to enhance the proficiency of the multidisciplinary health care team by providing evidence-based, fair-balanced CME/NCPD/CPE activities that address identified professional practice gaps and unmet educational needs.

We partner with key opinion leaders, academic/research institutions, professional societies, peer-reviewed journals, and social media platforms to develop and deliver the most innovative educational programming in health care.


Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy

STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to dose reductions or discontinuation of treatment. In one study, among 105 patients receiving paclitaxel for breast cancer, 36.2% needed dose reductions due to CIPN (Timmins et al, 2021). Whereas in some patients the symptoms improve with time, in o...
i3 Health

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

STATEMENT OF NEED Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and ren...
i3 Health

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact pat...
i3 Health

Exploring Advances in the Early Diagnosis and Treatment of Alzheimer Disease

STATEMENT OF NEED Alzheimer disease, the most common form of dementia among older adults, is a slowly progressive neurogenerative disease that affects approximately 6 million Americans aged 65 and older (Rajan et al, 2021). Symptoms of Alzheimer disease include memory loss, confusion, impulsive behavior, difficulty with language, mood and personality changes, hallucinations, and increased anx...
i3 Health

Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults

STATEMENT OF NEED Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results ...
i3 Health

Exploring Novel Treatments for Rett Syndrome

STATEMENT OF NEED Rett syndrome is a rare, debilitating neurodevelopmental disorder almost always associated with a spontaneous mutation in the methyl-CpG-binding protein 2 (MECP2) gene on the X-chromosome. Affected individuals experience loss of purposeful hand skills, abnormalities in gait, loss of spoken language, and stereotypic hand movements, with more severe manifestations including se...
i3 Health

Hitting the Target in HER2-Positive Metastatic Colorectal Cancer

STATEMENT OF NEED An estimated 153,020 new cases of colorectal cancer (CRC) are diagnosed annually, and 52,550 people die of the disease (Siegel et al, 2023). Approximately 22% of patients present with metastatic disease, which is associated with a dismal 5-year survival rate of 15% (SEER, 2022). Targeting biomarkers is a key strategy for expanding therapeutic options and improving outcomes i...
i3 Health

Leveraging the Growing Arsenal of Adjuvant Therapies for Early-Stage NSCLC

In this activity, Dr. Helena A. Yu, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, will provide insights into strategies for leveraging the growing arsenal of adjuvant therapies for early-stage non"small cell lung cancer (NSCLC), including treatment selection and adverse event management. Start the activity now! STATEMENT OF NEED Lung cancer is the second mos...
i3 Health

Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View

STATEMENT OF NEED Immune checkpoint inhibitors, which alter immune regulatory pathways and promote cell-mediated destruction of tumor cells, have revolutionized the treatment of cancer in recent years, with numerous therapeutic agents approved and several targets under investigation (Chennamadhavuni et al, 2022). However, up to 90% of patients receiving immune checkpoint inhibitors experience i...
i3 Health

Nursing Management of Tumor Lysis Syndrome

STATEMENT OF NEED Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current...
i3 Health

Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer: Case Explorations and Answers to FAQs

STATEMENT OF NEED Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for approximately 10% to 15% of breast cancer diagnoses and is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). TNBC is more common in Black women and in women under the age of 40 (ACS, 2023). Compared with other subtypes...
i3 Health

Putting the Freeze on Cold Agglutinin Disease

STATEMENT OF NEED Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpit...
i3 Health

Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC)...
i3 Health

Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sarcoma

STATEMENT OF NEED Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for th...
i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map